CORPORATE

First shipments of plasma from Porto and Lisbon were received in the beginning of February

Five centers acquired in the Czech Republic

Announced appointment of Ugo Di Francesco as CEO

Prestigious recognition presented for the first ever treatment for Plasminogen Deficiency

Guaranteeing equitable access to treatment is the central theme of the 2022 edition

Exclusive agreement signed for the distribution of a novel iron-based therapy

Scope is supplying Immunoglobulins to meet patient demand in France

Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency